Ray Funahashi, M.D. Email & Phone Number

Boston, Ma, Us

Cambridge, Ma, Us

MGB Innovation oversees the intellectual property (IP) stemming from Harvard University's $2 billion health research enterprise, which involves 80,000 employees and faculty. It exclusively handles industry collaboration, investment, international consulting, start-up creation, licensing, and innovation management.• Spearhead enterprise Generative AI initiative and designing AI solutions• Engineered and deployed an enterprise-level automated inbox management tool for patent correspondence on MGB Azure. Technologies used include Graph API, OpenAI, Langchain, Azure Storage, Azure SQL, Key Vault, Azure Storage, Azure OCR, Docker, Azure DevOps, Azure CI/CD Pipelines, Azure Functions, and Prompt Engineering.• Advise on AI investments and inventions• Support Licensing Managers in technology commercialization, triaging invention disclosures and conducting market analyses at Mass General Brigham, a globally-leading academic medical system.• Assist in outreach, drafting, and negotiating commercial agreements.

Merck Digital Sciences Studio Ventures• Due diligence on startups for Merck Digital Sciences Studio, evaluating potential investments and accelerator startups across biotech, medtech, AIU.S.-based Therapeutics Investment Firm (undisclosed)• Building a proprietary LLM-based tool for researching therapeuticsMIT Sandbox• Advise MIT Sandbox DHIVE healthcare entrepreneurship program and MIT student ventures.

Cambridge, Massachusetts, Us

Helping to build a clinical AI validation technology platform and service that enables hospitals and AI developers to test algorithm performance together while safely protecting patient data privacy. Medical AI is a potential game-changer, with a projected market to exceed $208 billion by 2030. Yet nearly all clinical AI algorithms are set up to fail in widespread clinical practice because of inadequate testing. Studies show that all medical algorithms have biases, including gender, age, race/ethnicity, geography, clinical conditions, and even medical imaging scanner brand. However, most hospitals today don't have the IT capability to test AI solutions scalably. With Gesund, we bridge the gap to robust, safe, and effective clinical AI.

Culver City, Ca , Us

A360 Fellows selected by Peter Diamandis come from around the globe and are a cohort of moonshot entrepreneurs, engineers, and inventors impassioned about exponential technologies and an abundance mindset.Abundance 360 (A360) is Peter Diamandis’ curated, global community of 360 entrepreneurs, executives, investors and industry leaders committed to understanding and leveraging exponential technologies to transform their businesses.

Pittsburgh, Pa, Us

• Chief Visionary and Co-Founder of a new medical innovation center connecting two world-class universities (Pittsburgh and Carnegie Mellon) and $23 billion global health enterprise UPMC.

Pittsburgh, Pennsylvania, Us

• Aiding the commercial development of a human Organs-on-a-Chip workflow and database platform to increase the potential of organs-on-a-chip technology and adoption.Organs-on-a-chips are an emerging way to develop better medical therapies by using human patient cells instead of animals. A patient's cells are transformed to stem cells, then into organ cell types that replicate functions (like the liver or brain). These cell groups are connected with a 3D microfluidic "blood flow" system. This creates a miniature "human" via a cell-organ collection on which drugs can be better developed and customized to a patient's own genome-- all while avoiding animal testing. However, these systems generate a tremendous volume of scattered and raw data that needs to be standardized across the industry so that stakeholders can use organs-on-a-chip technology effectively.Organs-on-a-chip is also referred to as Tissue Chip, Microphysiological System (MPS), Biomimetic systems

Pittsburgh, Pennsylvania, Us

Labkind is a mission to democratize the solving of global challenges by connecting every science research laboratory in the world to the ordinary person with a single online coordination platform. Utilizes artificial intelligence (AI) to streamline multidisciplinary collaboration and communication between research labs. • 2nd place at Startup Pitt Blitz 2016• 4th prize at Randall Big Idea Competition 2016• Idea Foundry Accelerator 2018-2019 (www.ideafoundry.org)

New York, New York, Us

Bioengineered human patient iPSCs and all neural lineage cells from embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)• Astrocytes, motor neurons, and neural stem cells, and reporter line design and engineering

New York, Ny, Us

Project A.L.S. Jenifer Estess Laboratory of Stem Cell Research• Differentiated and genomically engineered human motor neurons from A.L.S.-patient induced pluripotent stem cells (iPSCs) and neural stem cells (NSCs)

Bethesda, Md, Us

• Co-invented and patented: Engineering neural stem cells using homologous recombination• Genomically engineered human neural stem cells for the production of reporter and multi-functional lines• Differentiated human astrocytes and neurons in vitro• BHI Commercialization Consulting Club

Bethesda, Md, Us

Healthcare Disparities Research Fellowship Program• Conducted research into socioeconomic factors in healthcare disparities• Design and implementation of volunteer-driven health education intervention workshops in Women’s shelter in Washington DC

West Chester, Pennsylvania, Us

RNAi knockdown of male-mating behavior neuropeptide receptors in pond snail Lymnaea stagnalisPI: Gregg Phares, PhD

Doctor Of Medicine - Md

Graduate Foundations Certificate

Bachelor Of Science (Bs), Cell And Molecular Biology

Full Stack Web And Mobile App Developer, Computer Science

Business Management, Violin Performance

High School Diploma